Background: Increased IL-17A production has been associated with more severe asthma; however, the mechanisms whereby IL-17A can contribute to IL-13-driven pathology in asthmatic patients remain unclear. Objective: We sought to gain mechanistic insight into how IL-17A can influence IL-13-driven responses.
Methods: The effect of IL-17A on IL-13-induced airway hyperresponsiveness, gene expression, mucus hypersecretion, and airway inflammation was assessed by using in vivo models of IL-13-induced lung pathology and in vitro culture of murine fibroblast cell lines and primary fibroblasts and human epithelial cell lines or primary human epithelial cells exposed to IL-13, IL-17A, or both. Results: Compared with mice given intratracheal IL-13 alone, those exposed to IL-13 and IL-17A had augmented airway hyperresponsiveness, mucus production, airway inflammation, and IL-13-induced gene expression. In vitro, IL-17A enhanced IL-13-induced gene expression in asthma-relevant murine and human cells. In contrast to the exacerbating influence of IL-17A on IL-13-induced responses, coexposure to IL-13 inhibited IL-17A-driven antimicrobial gene expression in vivo and in vitro. Mechanistically, in both primary human and murine cells, the IL-17A-driven increase in IL-13-induced gene expression was associated with enhanced IL-13-driven signal transducer and activator of transcription 6 activation. Conclusions: Our data suggest that IL-17A contributes to asthma pathophysiology by increasing the capacity of IL-13 to activate intracellular signaling pathways, such as signal transducer and activator of transcription 6. These data represent the first mechanistic explanation of how IL-17A can directly contribute to the pathogenesis of IL-13-driven pathology. (J Allergy Clin Immunol 2017;139:462-71.)
Key words: Asthma, IL-13, IL-17A, signal transducer and activator of transcription 6, cytokines, signal transduction IL-13 has been ascribed a central pathogenic role in experimental models of asthma because exogenous IL-13 induces mucus hypersecretion, airway hyperresponsiveness (AHR), and airway remodeling. [1] [2] [3] [4] Moreover, eliminating IL-13 signaling abrogates allergen-driven responses, and selective restoration of IL-13 signaling in airway epithelial cells or smooth muscle cells is sufficient to recapitulate most features of allergic asthma. 5, 6 This suggests that IL-13-induced responses in pulmonary structural cells are critical to asthma pathogenesis. Recently, T H 17 cytokines have been shown to influence the development and severity of asthma, and murine models eliciting mixed T H 2/T H 17 responses are associated with more severe airway inflammation and dysfunction than purely T H 2-driven models. 7, 8 Similar to IL-13, IL-17A signaling in airway smooth muscle cells also influences AHR, 9 suggesting that the convergence of IL-13 and IL-17A signaling in pulmonary structural cells can contribute to the pathogenesis of severe forms of allergic asthma.
In human subjects IL-17A levels in lung biopsy specimens, sputum, and serum correlate with asthma severity, [10] [11] [12] [13] [14] and a unique subset of IL-4 1 /IL-17A 1 CD4 1 T cells (T H 2/T H 17 cells) was recently identified in the blood, bronchoalveolar lavage (BAL) fluid, and lungs of asthmatic patients. [15] [16] [17] Asthmatic patients with a predominance of T H 2/T H 17 cells in the BAL fluid (''T H 2/T H 17 predominant'') exhibited the greatest airway obstruction, hyperreactivity, and steroid use relative to ''T H 2-predominant'' or ''T H 2/T H 17-low'' subgroups. 16 Although these studies suggest a link between IL-17A and severe asthma in human subjects, the mechanisms whereby IL-17A influences disease severity, especially in subjects with mixed T H 2/T H 17 phenotypes, remain unclear.
Recent studies directed at determining how IL-17A regulates the development of IL-13-induced lung pathology have examined the effect of different doses or cellular sources of IL-17A. 7, 9, 18, 19 However, an important unanswered question is how interactions between IL-13 and IL-17A at the cellular and molecular levels influence asthma pathogenesis. Hence the aim of the present study was to determine molecular mechanisms by which IL-17A enhances IL-13 pathology in patients with severe asthma by using in vivo models of IL-13-induced lung pathology and in vitro cultures of relevant cell types.
METHODS
For a complete description of the materials and methods used in the murine and in vitro experiments, please see the Methods section in this article's Online Repository at www.jacionline.org.
Human subjects and nasal epithelial cell sampling
Nasal epithelial cells (NECs) were obtained from healthy donors at Cincinnati Children's Hospital Medical Center. Cells were collected after obtaining informed consent, and all studies were approved by the institutional review board (IRB#2008-0711). Nasal mucosa was sampled, as described elsewhere. 20 To expand primary NECs, cells were resuspended in basic epithelial cell growth medium (Lonza, Walkersville, Md) and cultured in an upright T25 flask, changing medium every 48 hours. Once confluent, cells were expanded in a T25 flask lying flat until confluent. Fifty thousand cells were then transferred into 24-well plates and allowed to reach confluence. Once confluent, cells were treated with cytokines, as described in the Methods section in this article's Online Repository at www.jacionline.org.
Statistical analysis
Data are expressed as means 6 SEMs. One-way ANOVA followed by the Tukey-Kramer test was used to determine differences between multiple groups. For comparison between 2 groups, a Student t test was performed.
Figures were produced and statistics were analyzed with GraphPad Prism 5 (GraphPad Software, La Jolla, Calif).
RESULTS

IL-17A increases IL-13-induced pathology in vivo
A/J mice were treated intratracheally with PBS, IL-13 (2 or 5 mg), IL-17A (2 or 5mg), or both on days 0, 3, and 6 to examine the effect of IL-17A on IL-13-induced lung pathology. AHR, airway inflammation, mucus production, and gene expression were assessed on day 7. Although treatment with IL-17A alone did not alter AHR, treatment with IL-13 induced AHR (Fig 1, A and B) . Treatment with 5 mg but not 2 mg of IL-17A enhanced AHR induced by 5 mg of IL-13 (Fig 1, B) . Treatment with 5 mg of IL-13 and IL-17A did not increase T H 2 cytokine expression in the BAL fluid or total IgE levels in the serum (see Fig E1 in this article's Online Repository at www.jacionline.org). Furthermore, although neither cytokine alone was administered at sufficiently high concentrations to increase total BAL cell numbers, simultaneous treatment with IL-13 and IL-17A increased BAL cell numbers (Fig 1, C and D) , primarily because of an increased frequency of neutrophils (Fig 1, E and F) . To examine goblet cell hyperplasia, we assessed levels of chloride channel, calcium activated 3 (CLCA3), a protein highly expressed in murine goblet cells, in lung homogenates from cytokine-treated animals (Fig 1, G) . IL-17A treatment did not increase CLCA3 protein in the lung, but treatment with IL-13 induced CLCA3 production in a dosedependent manner, and IL-13-induced CLCA3 levels were further enhanced by both doses of IL-17A. Thus IL-17A exacerbates IL-13-driven AHR, airway inflammation, and mucus production.
Reciprocal coregulation of IL-13-and IL-17A-induced genes in vivo Transcript levels of IL-13-induced genes were assessed in animals treated with 5 mg of IL-13 and IL-17A because consistent enhancement of IL-13-induced AHR, inflammation, and mucus was observed at these doses. Treatment with IL-13 induced expression of Tff2, Arg1, C3, Alox15, and Ca2 and the gene encoding the IL-13 decoy receptor Il13ra2 (Fig 1, H) . Although IL-17A treatment alone had little effect on expression of these genes, cotreatment with IL-17A enhanced IL-13-induced expression of these genes by nearly 3-fold. IL-17A-mediated enhancement of IL-13-induced lung pathology was not a result of increased expression of the IL-13 receptor because type II IL-4/ IL-13 receptor (Il13ra1 and Il4ra) transcript levels were unchanged (see Fig E2, A and B, in this article's Online Repository at www.jacionline.org).
In contrast to the enhancing effect of IL-17A on IL-13-induced gene expression, we found that expression of S100a8, S100a9, Lcn2, Csf2, Cebpb, and Cebpd was increased in animals exposed to IL-17A alone but diminished in animals coexposed to IL-17A and IL-13 (Fig 1, I ). The inhibitory effect of IL-13 on IL-17A-induced gene expression was also independent of changes in IL-17A receptor levels because expression of IL-17A receptor subunits (Il17ra and Il17rc) was unaltered (see Fig E2, C and D) . Collectively, these data suggest that there is reciprocal coregulation of IL-13-and IL-17A-induced genes in vivo.
IL-13 receptor a2 is not required for IL-17A-mediated enhancement of IL-13 pathology Despite its reported role as an IL-13 inhibitor, [21] [22] [23] allergendriven AHR is attenuated in IL-13 receptor (IL-13R) a2 2/2 mice, 24 suggesting that IL-13Ra2 might be required for maximal induction of AHR. To determine whether enhanced expression of Il13ra2 contributes to IL-17A-mediated enhancement of IL-13-driven pathology, IL-13-induced AHR, inflammation, and gene expression were measured in wild-type (WT) BALB/c or IL-13Ra2 2/2 mice after intratracheal treatment with 5 mg of cytokines. Although AHR was attenuated in IL-13Ra2 2/2 animals relative to WT mice, treatment with IL-17A still enhanced IL-13-driven AHR in IL-13Ra2 2/2 mice (Fig 2, A) . Despite differences in the magnitude of basal and IL-13-induced AHR, IL-17A enhanced IL-13-induced AHR by approximately (Fig 1, A and B) ; total cell counts from BAL fluid of cytokine-treated animals (Fig 1, C and D) ; frequency of macrophages, lymphocytes, neutrophils, and eosinophils in the BAL fluid (Fig 1, E and F) ; CLCA3 and a-tubulin expression and densitometry in total lung homogenates (Fig 1, G) ; and total lung expression of IL-13-induced (Fig 1, H) and IL-17A-induced (Fig 1, I ) transcripts after cytokine treatment. #P < .05, ##P < .01, and ###P < .001 versus PBS. 1P < .05, 11P < .01, and 111P < .001 versus IL-13. Means 1 SEMs of 4 to 9 mice per group (pooled over 3 independent experiments) are shown.
1.4-fold in both WT and IL-13Ra2
2/2 animals (see Fig E3, A, in this article's Online Repository at www.jacionline.org), suggesting that the effects of IL-17A were comparable in both strains. Similar to our observations in A/J mice, IL-17A enhanced IL-13-driven changes in BAL cellularity (Fig 2, B) , increased the frequency of neutrophils in the BAL (Fig 2, C and D) , and increased IL-13-driven transcript levels in the lung (Fig 2, E) . Furthermore, although IgE levels were significantly increased in the serum of IL-13Ra2 2/2 mice relative to WT mice, antibody levels were not altered by cytokine treatment in either strain (see Fig E3,  B) . IL-13 also diminished the expression of IL-17A-induced genes in both WT and IL13Ra2 2/2 mice (Fig 2, F) . Collectively, these data suggest that the ability of IL-17A to enhance IL-13-induced lung pathology is not dependent on IL-13Ra2. Furthermore, because IL-17A enhanced IL-13-induced pathology in both A/J (Fig 1) and BALB/c (Fig 2) animals, this suggests these in vivo observations are not limited to a single mouse strain.
Reciprocal coregulation of IL-13-and IL-17A-induced genes in vitro
To confirm that changes in gene expression reflected changes in transcriptional activity and not altered inflammatory cell recruitment, we expanded our studies to an in vitro analysis of fibroblasts, an IL-13-and IL-17A-responsive structural cell type. Initial dose-finding experiments with NIH/3T3 fibroblasts revealed strong induction of the IL-13-responsive genes C3 and Il13ra2 at 100 ng/mL (see Fig E4 in this article's Online Repository at www.jacionline.org). Subsequently, IL-13-induced gene expression was examined over a 24-hour period. As in the whole lung, treatment with IL-13 by itself again augmented both C3 and Il13ra2 expression, whereas IL-17A did not increase Il13ra2 expression and resulted in only modest expression of C3 (Fig 3, 
org). In cocultures of WT and IL-17RA
2/2 cells, IL-13 induced similar levels of C3 and Il13ra2 expression (Fig 4, A and B) . However, in WT and IL-17RA 2/2 cocultures treated with both cytokines, IL-17A enhanced IL-13-dependent C3 and Il13ra2 expression in the WT cells but not the IL-17RA 2/2 cells. IL-17A-induced expression of Lcn2 was abrogated in IL-17RA 2/2 fibroblasts, confirming their insensitivity to IL-17A (Fig 4, C) . Overall, these data demonstrate that IL-17A-induced mediators cannot enhance IL-13-induced gene expression in the absence of functional IL-17A receptors, suggesting that IL-17A acts directly on IL-13-responsive cells to increase IL-13-induced transcriptional activity.
IL-17A does not enhance the stability of IL-13-induced transcripts IL-17A synergizes with innate cytokines (TNF-a and IL-1b) by increasing target mRNA stability. [25] [26] [27] NIH/3T3 cells were incubated with IL-13 alone or in combination with IL-17A for 16 hours to determine whether IL-17A also regulates the stability of IL-13-induced transcripts. Then de novo transcription was blocked with actinomycin D, and mRNA degradation was evaluated over a 24-hour period. As expected, IL-17A improved the stability of TNF-a-induced Csf3 and Lcn2 (see Fig E7 in 2/2 mice treated intratracheally with IL-13 or IL-17A (Fig 2, A) ; total cell counts from BAL fluid of cytokine-treated animals (Fig 2, B) ; frequency of macrophages, lymphocytes, neutrophils, and eosinophils in BAL fluid (Fig 2, C and D) ; and total lung expression of IL-13-induced (Fig 2, E) and IL-17A-induced (Fig 2, F) IL-17A enhances IL-13-driven signal transducer and activator of transcription 6 phosphorylation
Because IL-13-driven lung pathology requires signal transducer and activator of transcription 6 (STAT6) expression, 5 we evaluated the hypothesis that IL-17A augments IL-13-driven pathology by promoting activation of STAT6. To test this, NIH/3T3 cells were incubated with medium containing IL-13, IL-17A, or both, and phosphorylated STAT6 (pSTAT6) was evaluated by means of Western blotting. Stimulation with IL-13 induced STAT6 phosphorylation (Fig 6, A) . Although IL-17A did not increase STAT6 phosphorylation, cotreatment with IL-17A enhanced IL-13-driven STAT6 activation (Fig 6, A) . Pretreatment of NIH/3T3 cells with cycloheximide did not limit the ability of IL-17A to enhance IL-13-dependent STAT6 phosphorylation (Fig 6, B) . In fact, pSTAT6 levels were comparably increased (approximately 1.7 fold) in dimethyl sulfoxide-and cycloheximide-exposed cultures (Fig 6, C) , suggesting that IL-17A-mediated enhancement of IL-13-dependent pSTAT6 does not require de novo protein synthesis.
We also assessed STAT6 phosphorylation in cytokine-treated NIH/3T3 cells by using phosphoflow cytometry. Compared with IL-13-exposed cells, cells stimulated with IL-13 and IL-17A demonstrated significantly greater levels of pSTAT6 after 2 and 5 minutes of stimulation (Fig 6, D, Based on these in vitro observations, we wanted to determine whether IL-17A also enhanced IL-13-driven STAT6 phosphorylation in vivo. Thus pSTAT6 and total STAT6 levels were measured in whole lung homogenates from A/J mice treated with PBS, 5 mg of IL-13, 5 mg of IL-17A, or 5 mg of both cytokines by means of Western blotting. Twenty-four hours after the final cytokine exposure, pSTAT6 was detectable in IL-13-treated animals but not PBS-or IL-17A-exposed animals, and IL-13-induced pSTAT6 levels were further heightened by IL-17A (Fig 6, E) . Thus we observe an association between increased pulmonary pSTAT6 levels, AHR, airway inflammation, and mucus production in animals exposed to IL-13 and IL-17A.
Although STAT6 is the dominant signaling pathway activated in response to IL-13, additional pathways have been implicated in (Fig 3, A) , Il13ra2 (Fig 3, B) , Cebpd (Fig 3, C) , and Lcn2 (Fig 2, D) expression in NIH/3T3 cells stimulated with IL-13, IL-17A, or both cytokines over 24 hours. ##P < .01 and ###P < .001 versus medium. 1P < .05, 11P < .01, and 111P < .001 versus IL-13 (Fig 3, A and B) or IL-17A (Fig 3, C) . IL-13 signaling. [28] [29] [30] [31] To determine whether these signaling pathways can also contribute to IL-17A-mediated enhancement of IL-13 responses, we cultured lung fibroblasts from BALB/c WT or STAT6 2/2 mice in medium containing IL-13, IL-17A, or both cytokines and assessed the expression of IL-13-induced (Fig 6, E) and IL-17A-induced (Fig 6, F) genes. In WT cells treatment with IL-13 induced the expression of both Il13ra2 and C3, and expression was augmented by IL-17A. In contrast, IL-13-induced Il13ra2 and C3 expression was reduced in STAT6 2/2 fibroblasts, and IL-17A did not notably enhance expression further. IL-17A-induced expression of Lcn2 was inhibited by IL-13 in cells from WT but not STAT6 2/2 mice (Fig 6, F) , implying that inhibition of IL-17A signaling requires IL-13-induced STAT6 activation. Taken together, these findings suggest that IL-17A directly increases IL-13-induced gene expression through STAT6 activation, leading to enhanced IL-13-dependent lung pathology.
Reciprocal coregulation by IL-13 and IL-17A in human cells
Initial dose-finding experiments were carried out in normal human bronchial epithelial cells (ATCC CRL-4051) to determine whether IL-17A also augmented IL-13 activity in human cells. Although SERPINB4 expression was increased at all IL-13 concentrations tested (5-100 ng/mL), IL13RA2 expression was only induced by 100 ng/mL (see Fig E10 in this article' s Online Repository at www.jacionline.org). A dose of 100 ng/mL was selected for further study to ensure that potential regulatory influences of IL-13Ra2 would be present (see Fig E4) . To test the ability of IL-17A to enhance IL-13-induced gene expression in primary human cells, NECs were collected from 7 healthy volunteers, and IL-13-induced gene expression was assessed after treatment with IL-13, IL-17A, or both IL-13 and IL-17A. Treatment with IL-13 induced expression of SERPINB4 and IL13RA2 (Fig 7, A) , and although IL-17A alone did not remarkably influence expression of these genes, treatment with both cytokines further increased IL-13-induced transcript levels in the majority of subjects. Moreover, IL-13 also inhibited IL-17A-induced LCN2 expression (Fig 7, B) , demonstrating that our observations in mice are consistent in human primary cells.
To determine whether IL-17A also enhanced IL-13-driven STAT6 activation in human cells, human epithelial cell lines were incubated with medium containing IL-13, IL-17A, or both cytokines, and pSTAT6 levels were assessed by means of Western blotting. Both Caco-2 (Fig 7, C) and A549 (Fig 7, D) cells demonstrated greater levels of IL-13-induced pSTAT6 when costimulated with IL-17A. Finally, to confirm that IL-17A increased IL-13-induced pSTAT6 levels in primary human cells, NECs from 2 donors were additionally exposed to cytokines, and pSTAT6 levels were assessed by means of Western (Fig 4, A) , Il13ra2 (Fig 4, B) , and Lcn2 (Fig 4, C) expression in cocultured WT or IL-17RA 2/2 lung fibroblasts stimulated with IL-13, IL-17A, or both cytokines for 24 hours. #P < .05 and ###P < .001 versus medium. 11P < .01 and 111P < .001 versus IL-13 (Fig 4, A and B) or IL-17A (Fig 4, C) . (Fig 5, A) and Il13ra2 (Fig 5, B) in NIH/3T3 cells stimulated with IL-13 or IL-13 plus IL-17A for 16 hours and incubated with actinomycin D (ActD). Real-time PCR analysis of transcript levels was evaluated over 24 hours, and t½ was calculated. blotting. As shown in Fig 7, E, cells from both donors demonstrated IL-13-induced pSTAT6, which was further enriched in the presence of IL-17A. Overall, these results demonstrate that IL-17A enhances IL-13 activity across a panel of asthmarelevant human epithelial cells, suggesting a plausible mechanistic explanation for increased asthma severity in subjects who simultaneously produce measurable levels of both IL-13 and IL-17A.
DISCUSSION
Despite reports of increased IL-17A production in patients with severe asthma, [10] [11] [12] [13] [14] [15] [16] [17] little is known about how IL-17A influences IL-13-driven responses. We propose a novel pathway in which IL-17A enhances IL-13-induced signaling and gene expression both in vitro and in vivo. IL-17A-mediated enhancement of IL-13 signaling and gene expression occurs rapidly and requires IL-17RA expression in IL-13-responsive cells. It is not a result of altered IL-13 receptor expression and is independent of molecular processes driving synergy between IL-17A and other proinflammatory mediators (ie, TNF-a). Mechanistically, we observe that IL-17A enhances IL-13-dependent activation of a key mediator of allergic responses: STAT6.
Whether increased STAT6 phosphorylation is sufficient to explain IL-17A-mediated enhancement of IL-13 activity is unclear. However, our observation that IL-17A does not enhance IL-13-induced gene expression in STAT6
2/2 cells suggests that other IL-13-activated pathways (insulin receptor substrate 2 and signal transducer and activator of transcription 3) [29] [30] [31] are not required. Furthermore, although the mechanisms through which IL-17A enhances IL-13-driven pSTAT6 accumulation are unknown, binding to DNA is known to limit dephosphorylation and nuclear export of pSTAT6. 32 Thus IL-17A signaling might facilitate pSTAT6 accumulation by increasing the number of available pSTAT6 DNA binding sites. Supporting this possibility, nuclear factor kB and CCAAT-enhancer binding Fig 6, A) or cycloheximide (Fig 6, B) and then stimulated with cytokines for 5 minutes (Fig 6, C) ; densitometry of pSTAT6/STAT6 expression shown in Fig 6, A and B ; geometric mean fluorescence intensity of pSTAT6 by using phosphoflow in NIH/3T3 cells stimulated with cytokines over 1 hour (Fig 6, D) ; pSTAT6 and STAT6 expression and associated densitometry in whole lung homogenates from cytokine-treated A/J mice (means 1 SEMs of n 5 7-10 mice per group, pooled from 3 independent experiments (Fig 6, E) ; or real-time PCR analysis of C3 and Il13ra2 (Fig 6, F) or Lcn2 (Fig 6, G) protein binding sites are found in the promoters of IL-17A-enhanced IL-13-induced genes. [33] [34] [35] [36] IL-17A-mediated inhibition of suppressor of cytokine signaling protein induction, which was previously demonstrated to negatively regulate IL-13 signaling, [37] [38] [39] might also play a role. However, the enhancing effects of IL-17A on IL-13-induced STAT6 activation are exerted rapidly (< _5 minutes). As such, it is likely that the effects of IL-17A on IL-13 are related to membrane-proximal factors, perhaps those directly interacting with the IL-13R complex, or associated kinases. To this end, IL-17A signaling might directly alter the activity of intracellular phosphatases previously reported to regulate pSTAT6 accumulation, including PP2A, 40 PTP1B, 41 SHP1, 42 or SHP2. 43 Alternatively, because IL-17A activates TRAF6, an E3 ubiquitin ligase, it is conceivable that ubiquitination of STAT6 or other IL-13 signaling components might be altered in IL-17A-exposed cells. Consistent with this possibility, STUB1, 44 GRAIL, 45 and CBL-b 46 have been shown to influence IL-13-driven responses through ubiquitination-dependent pathways. These possibilities are the subject of ongoing investigation in our laboratory.
Although our data are consistent with previous reports demonstrating IL-17A-mediated enhancement of IL-13 pathology, 7, 8, 17, [47] [48] [49] protective roles for IL-17A in asthmatic patients have been reported in mouse models of asthma 18, 19 and respiratory syncytial virus-induced AHR. 50 In asthma models it appears that, when protective, IL-17A is produced primarily by gd T cells. For example, resolution of airway inflammation after allergen challenge is dependent on IL-17A produced by gd T cells. 19 Similarly, although widespread inhibition of IL-17A production was associated with reduced IL-13-driven pathology (suggesting a proasthmatic role for IL-17A), inhibition of IL-17A production by gd T cells exacerbated IL-13-driven pathology. 18 How IL-17A-producing gd T cells can limit IL-13-induced lung pathology remains unclear; however, additional factors produced by these cells might influence how IL-17A-derived signals are integrated. For example, others have shown that although IL-17A blockade limited allergen-induced airway eosinophilia and cytokine production in WT mice, IL-17A blockade exacerbated these parameters in IL-22 2/2 mice, 51 suggesting that the cytokine milieu influences protective versus proinflammatory effects of IL-17A. Alternatively, our observation that IL-17A-mediated enhancement of IL-13-induced gene expression requires IL-13 and IL-17A signaling in the same cell suggests that where IL-17A is produced is also an important determinant of its role in asthma pathology. Although gd T cells can be found equally distributed in the alveolar spaces, perivascularly, and within the visceral pleura, with slightly lower distribution near the smooth muscle and in the lamina propria, ab T cells (the likely source of IL-13) are found primarily in the alveolar spaces, 52 suggesting that the unique ability of gd-derived IL-17A to control IL-13-induced AHR might be related to its inability to influence IL-13-exposed cells. Because we did not observe altered frequency of IL-17A 1 gd T cells (or any T-cell subset producing IL-13 or IL-17A) in response to exogenous cytokine administration (see Fig E11 in this article' s Online Repository at www.jacionline.org), it is unlikely that the increased IL-13-driven pathology observed in our model was due to altered gd T-cell activity.
Another observation that has potentially broad implications is that IL-13 antagonizes IL-17A-induced expression of innate antimicrobial genes (Lcn2, S100A8, S100A9, and Csf2) in a STAT6-dependent manner. Because IL-17A-induced gene products are important for limiting the growth of bacterial and fungal microorganisms, our data might explain the link between atopic disease and disordered microbial colonization. [53] [54] [55] [56] . Reciprocal coregulation by IL-13 and IL-17A is conserved in human cells. A and B, Real-time PCR analysis of SERPINB4 or IL13RA2 (Fig 7, A) and LCN2 (Fig 7, B) expression in primary human NECs (n 5 7) stimulated with IL-13, IL-17A, or both cytokines for 24 hours. C-E, pSTAT6 and STAT6 levels and associated densitometric analysis in Caco-2 (Fig 7, C) or A549 (Fig 7, D) cells stimulated with cytokines for 5 minutes or NECs (n 5 2) stimulated with cytokines for 15 minutes (Fig 7, E) . Caco-2 and A549 immunoblots are representative of 2 and 3 independent experiments, respectively.
Furthermore, these results agree with a recent report demonstrating that patients with ''T H 2-high'' asthma exhibit less T H 17-associated gene expression and that IL-13 blockade exacerbates T H 17-associated inflammation. 57 Moreover, we contend that this counterregulation of IL-17A-induced gene expression by IL-13 might also explain why recent endotyping/ phenotyping studies have not consistently identified a role for T H 17 cells or IL-17A in patients with severe asthma. [58] [59] [60] [61] Finally, because reliably detecting IL-17A protein is difficult, even in subjects with identified ''T H 17-high'' asthma, 57 it is likely that identification of patients with T H 17-involved disease will be difficult because both the primary cytokine signal (IL-17A) 57, [62] [63] [64] [65] and the downstream gene expression can be suppressed by ongoing T H 2 inflammation. This challenge in identifying patients with IL-17A-associated asthma might suggest that inclusion of many patients with IL-17A-independent disease might have limited the efficacy of anti-IL-17RA therapy in patients with moderate-to-severe asthma in a recent clinical trial. 66 Collectively, our findings provide a mechanistic underpinning for the association between increased IL-17A levels and severe asthma. Given the essential role for IL-13 and STAT6 in AHR, airway inflammation, and mucus overproduction, our finding that IL-17A enhances IL-13-driven STAT6 phosphorylation has important implications for the pathogenesis of IL-13-induced disease. Moreover, it is interesting to note that common triggers of asthma exacerbations, such as upper respiratory tract infections with viral or bacterial pathogens, are potent triggers for T H 17-associated cytokine production. As such, it is plausible that similar interactions between IL-17A and IL-13 can also drive changes in disease status after infection.
Key messages
d IL-17A directly enhances IL-13-associated pathology by increasing IL-13-initiated STAT6 signaling.
d IL-13 antagonizes IL-17A activity through a STAT6-dependent mechanism.
d These findings provide the first mechanistic insight into how IL-17A can contribute to the development of more severe asthma and might explain previous observations of disordered microbial colonization in patients with atopic disorders. 
METHODS Mice
Treatment protocol
A/J, BALB/c, and IL-13Ra2 2/2 mice were treated intratracheally with PBS, 2 or 5 mg of rIL-13, 2 or 5 mg of rIL-17A, or a combination of both cytokines (BioLegend, San Diego, Calif, or eBioscience, San Diego, Calif) on days 0, 3, and 6 and killed on day 7 to measure AHR.
Analysis of AHR
AHR was evaluated by using the Airway Pressure Time Index technique, as described previously. E1 In brief, mice were anesthetized, intubated, and respirated at a rate of 120 breaths/minute with a constant tidal volume (0.2 mL) and paralyzed with decamethonium bromide (25 mg/kg). After a stable baseline was achieved, acetylcholine (50 mg/kg) was injected into the inferior vena cava, and dynamic airway pressure (centimeters of H 2 O 3 seconds) was recorded for 5 minutes. After AHR measurements, lung segments were snapfrozen for subsequent analysis by using real-time PCR and Western blotting. Lungs were lavaged 3 times with a 1.0-mL aliquot of cold Hanks' balanced salt solution (Invitrogen, Carlsbad, Calif) to collect BAL fluid. Recovered lavage fluid (70% to 80%) was centrifuged (300g for 8 minutes), and the cell pellet was resuspended in 1.0 mL of 10% FBS in 13 PBS. Total cells were counted with a hemocytometer. Slides were prepared by means of cytocentrifugation (Cytospin 4; Thermo Scientific, Waltham, Mass) and stained with Diff-Quik (Dade Behring, Deerfield, Ill). Differential counts were determined by using morphologic criteria under a light microscope with evaluation of 500 or more cells per slide.
Determination of T H 2 cytokine and IgE concentrations
BAL fluid and serum samples were collected from animals after AHR measurements and centrifuged at 3000g for 5 minutes to remove cell debris. BAL fluid concentrations of IL-4, IL-5, IL-9, and IL-10 and total serum IgE concentrations were measured by using ELISA (eBioscience).
Cell culture and cytokine treatment
All cells were maintained in a humidified incubator at 378C in a 5% CO 2 atmosphere. NIH/3T3, A549, and Caco-2 cells were maintained in Dulbecco modified Eagle medium supplemented with 10% FBS, 1% L-glutamine, and a 1% mixture of penicillin and streptomycin. Lung fibroblasts were maintained in RPMI supplemented with 10% FBS, 1% L-glutamine, a 1% mixture of penicillin and streptomycin, and 0.1% b-mercaptoethanol. During serum starvation, cells were grown in culture medium supplemented with 0.1% FBS. HBEC3-KT cells (ATCC CRL-4051) were maintained in Keratinocyte Serum Free Medium supplemented with Epidermal Growth Factor 1-53 and Bovine Pituitary Extract (Invitrogen). All cells were stimulated with IL-13 (100 ng/ mL), TNF-a (10 ng/mL), IL-17A (100 ng/mL), IL-13 plus IL-17A, or TNF-a plus IL-17A (eBioscience), unless otherwise noted, and harvested at indicated times.
Lung fibroblast cell culture
Lungs from BALB/c, C57BL/6, IL-17RA 2/2 , and STAT6 2/2 mice were excised, minced, and placed in 6 mL of serum-free RPMI containing Liberase CI (0.5 mg/mL; Roche, Mannheim, Germany), DNase I (0.5 mg/mL; Sigma, St Louis, Mo), 1% L-glutamine, a 1% mixture of penicillin and streptomycin, and 0.1% b-mercaptoethanol at 378C for 45 minutes. mRNA stability assay NIH/3T3 cells were grown in complete culture medium to confluence and then incubated in serum starve medium supplemented with IL-13, TNF-a, IL-13 plus IL-17A, or TNF-a plus IL-17A. Actinomycin D (5 mg/mL, Sigma) was added to cell cultures 12 (TNF-a 6 IL-17A) or 16 (IL-13 6 IL-17A) hours after cytokine treatment, and RNA was isolated before addition of actinomycin D and 2 (TNF-a 6 IL-17A) or 24 (IL-13 6 IL-17A) hours after addition of actinomycin D.
Cycloheximide assay
NIH/3T3 cells were grown in complete culture medium to confluence and then incubated in serum-starved medium supplemented with cycloheximide (5 mg/mL) or dimethyl sulfoxide (0.05% vol/vol) 2 hours before cytokine stimulation. Cells were stimulated in medium supplemented with IL-13, IL-17A, or both cytokines for 15 minutes. Protein lysates were immunoblotted for pSTAT6 (Tyr641) and total STAT6 (Cell Signaling, Danvers, Mass).
Flow cytometry
NIH/3T3 cells were grown in complete culture medium to confluence and then incubated in serum-starved medium supplemented with IL-13, IL-17A, or both for 2, 5, 15, 30, and 60 minutes. Cells were incubated with Trypsin-EDTA (0.05%, Invitrogen) for 5 minutes at 378C and then fixed for 10 minutes with 2% paraformaldehyde at room temperature and permeabilized in 90% methanol for 30 minutes at 48C. Cells were stored at 2808C in 90% methanol until staining. Cells were stained for 1 hour at 48C with anti-phospho-STAT6-phycoerythrin (PE; pY641; BD Biosciences, San Jose, Calif). Lung cells (1 3 10 6 ) were stimulated with phorbol 12-myristate 13-acetate (100 ng/mL) and ionomycin (1 mg/mL) for 16 hours and then Brefeldin A and monensin (eBioscience) were added for 4 hours to evaluate cytokine production by ab and gd T cells. Cells were fixed, permeabilized, and stained with anti-CD42PE-Cy7 (RM4-5), anti-CD90.22Brilliant Violet 605 (53-2.1; BD PharMingen), anti-CD32Brilliant Violet 650 (145-2C11; BD PharMingen), anti-TCRb2eFluor 450 (H57-597) anti2IL-17A2Ax647 (eBio17b7), and anti2IL-132PE (eBio13A). All mAbs were from eBioscience, unless otherwise indicated.
RNA purification and real-time PCR
Total cellular RNA was extracted with TRI Reagent (Molecular Research Center, Cincinnati, Ohio), according to the manufacturer's protocol, and reverse transcribed by using SuperScript II reverse transcriptase (Invitrogen). To assess IL-13-and IL-17A-induced message expression in lung sections and cell cultures, we used quantitative real-time PCR with SYBR Green mix (Bio-Rad Laboratories, Hercules, Calif). Expression levels were normalized to S14 (mouse) or S13 (human). RT-PCR primer sequences are indicated in Table E1 .
Western blotting of whole-lung homogenate (Fig E1, A) and total serum IgE levels (Fig E1, B) of A/J mice after intratracheal cytokine treatment. #P < .05, ##P < .01, and ###P < .001 versus PBS. Means 1 SEMs of 4 to 9 mice per group (pooled over 3 independent experiments) are shown. Fig E2, A and B) and IL-17A (Fig E2, C and D) receptor subunits in A/J mice after intratracheal cytokine treatment. Means 1 SEMs of 4 to 9 mice per group (pooled over 3 independent experiments) are shown. Fig E5, A and B) and IL-17A (Fig E5, C and D (Fig E7, A) and Lcn2 (Fig E7, B) in NIH/3T3 cells stimulated with TNF-a or TNF-a plus IL-17A for 12 hours and incubated with actinomycin D (ActD). Real-time PCR analysis of transcript levels was evaluated over 2 hours, and t½ was calculated. Results display means 6 SEMs of 4 replicates from 1 of 2 experiments performed. 1 IL-17A 1 CD4 1 T cells (Fig E11, A and B 
FIG E5. A-D, Real-time PCR analysis of -IL-13 (
